Alex Delaney-Gesing, Senior Editor

The amount of light effused by these round-shaped eyeglass frames are designed to match the exact wavelength of sunlight a user would be exposed to outside.

The company, formerly known as Clover Therapeutics, intends to use the funding to advance two lead drug candidates that target molecularly-defined AMD patient subtypes.

Maria Sampalis, OD, continues her dry eye discussion by sharing what factors she considers when diagnosing and treating patients.

Companies are entering an exclusive licensing agreement for the development and commercialization of Brimochol PF and Carbachol PF in three new regions: Greater China, South Korea, and select Southeast Asian territories.

The company's technology allows for ECPs to detect, monitor, and treat AMD 3 years before clinical diagnosis.

Researchers are investigating a 3D-printed self-moisturizing contact lens that could be a catalyst for the development of next-generation contact lens-based medical devices.

Oxurion NV finds insufficient evidence of efficacy on key clinical endpoints for THR-687 in Part A of the INTEGRAL phase 2 trial; focus will now turn to an alternative candidate and trial.

Maria Sampalis, OD, shares how she approaches starting the dry eye conversation when diagnosing her patients.

New detailed, longer-term findings were presented at the 2022 ARVO meeting.

Interim data findings on spectacles using SightGlass Vision Diffusion Optics Technology were presented at ARVO 2022.

Maria Sampalis, OD, shares the common habits her dry eye patients have that lead them to developing the disease.

Set for May 23-28, the global initiative aims to bring attention to the global epidemic of myopia cases in children.

The organizations will partner for a 90-day campaign to promote optometry awareness.

Duo commits to a second year working together after a year of achievements in addressing myopia management among ECPs.

Five recipients will receive funding to atttend this years ARVO meeting in Denver, Colorado.

New book offers guidelines for understanding and eliminating symptoms of eyestrain.

Trial data finds that CSF-1 (pilocarpine hydrochloride 0.4%), a preservative-free ophthalmic solution, met both its primary and secondary endpoints.

New activator features a single-piece eye cup and translucent design that allows for more efficient and accurate positioning in the eye.

Investigators report a correlation between the risk of 5-letter visual acuity (VA) loss at 24 months for eyes with clinically significant diabetic macular edema (CSDME) and good VA initially treated and eyes that were initially observed in routine clinical practice.

A new survey commissioned by the Contact Lens Institute found that US eye care practitioners are failing to take advantage of the opportunity to discuss contact lens options with 2 out of 3 patients. Two virtual panel discussions on May 3 will analyze the data.

Lois Schoenbrun, CAE (ret.), FAAO, previously served as executive director of the American Academy of Optometry.

Gifted by philanthropist James Grosfeld, the money will fund the launching of a pioneering research initiative as one of the largest investments of resources in the United States.

Changes in three new positions took effect this month.

As part of its partnership, Shamir will provide insight and expertise for sales development, customer service, as well as research and development

Nano Magic President/CEO Tom Berman continues his post-Vision Expo East discussion on the company's products as well as his key takeaways from this year's in-person meeting.

Nano Magic's Tom Berman discusses the company's origins and mission in creating nanotech-powered solutions.

Elevatum was created as a phase 4, multicenter, open-label, single-arm trial to specifically study Vabysmo (faricimab-svoa) in these underrepresented populations.

Sunlight in the classroom can be a protective measure against the development of myopia, researchers have found.

The partnership is in support of the company's latest dry eye relief campaign and part of the launch for its leading global artificial tear drop brand.